Coronary artery disease / hypoxia

Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the

Hypoxia inducible VEGF plasmid for ischemic disease

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION This invention relates to gene therapy. More particularly, this invention relates to a plasmid system for increased expression of vascular endothelial growth factor (VEGF) under hypoxia conditions. The plasmid system can be used for treating ischemic disease in a person

Methods for increasing the stabilization of hypoxia inducible factor-.alpha.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

ShRNA gene therapy for treatment of ischemic heart disease

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is in the fields of treatment for cardiac disease, treatment of ulcers, gene therapy and molecular imaging. 2. Background of the Invention Coronary artery disease is the leading cause of morbidity and mortality in the Western

Inhibitors of HIF and angiogenesis

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD The present disclosure is generally directed to inhibitors of the Hypoxia Inducible Factor (HIF) pathway and their methods of use including anti-tumor therapies and disorders leading to ischemia (stroke, ischemic heart disease etc.) as well as non-cancerous angiogenic diseases (rheumatoid

Pyridone substituted benzothiazole derivatives

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION The present invention generally relates to pyridone substituted benzothiazole compounds that are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A.sub.2A -receptor and a high selectivity to the A.sub.1 - and

Benzathiazol-acetamides

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive

Benzothiazole derivatives

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive

Carbohydrate composition extracted from Panax ginseng and its use in the treatment of ischemic conditions

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

TECHNICAL FIELD The present invention relates to methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition. The ischemic condition is especially but not exclusively ischemic heart disease and

coronary artery disease/hypoxia

Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Hypoxia inducible VEGF plasmid for ischemic disease

Methods for increasing the stabilization of hypoxia inducible factor-.alpha.

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

ShRNA gene therapy for treatment of ischemic heart disease

Inhibitors of HIF and angiogenesis

Pyridone substituted benzothiazole derivatives

Benzathiazol-acetamides

Benzothiazole derivatives

Carbohydrate composition extracted from Panax ginseng and its use in the treatment of ischemic conditions

Database tanaman obat terlengkap yang didukung oleh sains